In contrast, 60% of the ESR1-negative tumours (group B), which show the highest expression of NFκB2 and RELB, harboured missense mutations in BRCA1, which could produce aberrant proteins but conserving some activities such as the capacity to activate the NFκB machinery. The gene discussed is NFKB1; the disease is neoplasm.